---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000798269.md"
description: "Novo Nordisk remains a world-class company with leading diabetes and obesity treatments, but I'm re-evaluating my investment. Competition in the obesity market is intensifying, and future growth may become less predictable. I may eventually switch to a healthcare company with a more diversified business and lower execution risk while continuing to monitor Novo Nordisk's progress."
datetime: "2026-07-15T16:46:27.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000798269.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000798269.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000798269.md)
author: "[melph](https://longbridge.com/en/profiles/20208463.md)"
generator: "portal-rs"
---

# Novo Nordisk remains a world-class company with le…


### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**